
Opinion|Videos|December 14, 2023
An Overview of Institution-Led Programs for Bispecific Engager Administration
Author(s)Brooke Peters, PharmD, BCOP
Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5

















